Invetech Videos

1. The Power Of Partnerships And The Rise Of iPSC 5/23/2025

   During the Cell & Gene Live, Unlocking the Potential of iPSC Therapies in Regenerative Medicine, Julie Allickson, Ph.D., Chief Technology Officer at Mayo Clinic's Center for Regenerative Biotherapeutics and Erin Kimbrel, Ph.D., Head of Cell & Gene Therapy Research at Astellas emphasize that partnerships and collaboration are essential to advancing regenerative medicine and iPSC-based therapies.

2. Why iPSC Is Research Thriving 5/23/2025

   In this first segment of Cell & Gene Live, Unlocking the Potential of iPSC Therapies in Regenerative Medicine, Julie Allickson, Ph.D., Chief Technology Officer at Mayo Clinic's Center for Regenerative Biotherapeutics and Erin Kimbrel, Ph.D., Head of Cell & Gene Therapy Research at Astellas highlight the transformative potential of regenerative medicine and iPSC-based therapies. They emphasize the versatility and scalability of pluripotent stem cells, particularly for allogeneic applications that could eliminate the need for immunosuppression. These advances hold promise for treating complex diseases like diabetes, multiple sclerosis, and cardiac conditions, with the goal of making therapies more accessible and impactful on a global scale.

3. Gene Editing Innovations Driving The Future Of iPSC Therapies 5/23/2025

   In this part of our discussion during the Cell & Gene Live, Unlocking the Potential of iPSC Therapies in Regenerative Medicine, Julie Allickson, Ph.D., Chief Technology Officer at Mayo Clinic's Center for Regenerative Biotherapeutics and Erin Kimbrel, Ph.D., Head of Cell & Gene Therapy Research at Astellas agree that ophthalmology, neurodegenerative diseases (such as Parkinson’s and Alzheimer’s), type 1 diabetes, and cardiovascular conditions are among the most promising areas for iPSC-based therapies over the next 3–5 years.

4. Overcoming Manufacturing Hurdles To Scale iPSC Therapies 5/23/2025

   In this part of our discussion during the Cell & Gene Live, Unlocking the Potential of iPSC Therapies in Regenerative Medicine, Julie Allickson, Ph.D., Chief Technology Officer at Mayo Clinic's Center for Regenerative Biotherapeutics and Erin Kimbrel, Ph.D., Head of Cell & Gene Therapy Research at Astellas discussed the key manufacturing and scalability challenges in bringing iPSC-derived therapies to market under GMP conditions.

5. Regulatory Challenges And Future Outlook For iPSC Therapies 5/23/2025

   In this part of our discussion during the Cell & Gene Live, Unlocking the Potential of iPSC Therapies in Regenerative Medicine, Julie Allickson, Ph.D., Chief Technology Officer at Mayo Clinic's Center for Regenerative Biotherapeutics and Erin Kimbrel, Ph.D., Head of Cell & Gene Therapy Research at Astellas discussed key regulatory challenges for iPSC-based therapies, including donor cell sourcing, genetic modification risks, and long-term safety concerns like tumorigenicity.

6. Unlocking The Potential Of iPSC Therapies In Regenerative Medicine 5/23/2025

   During this final segment of Cell & Gene Live, our expert panelists, Julie Allickson, Ph.D., Chief Technology Officer at Mayo Clinic's Center for Regenerative Biotherapeutics and Erin Kimbrel, Ph.D., Head of Cell & Gene Therapy Research at Astellas, answered audience questions pertaining to the unique challenges facing iPSC, such as managing off-target effects, ensuring safety of master cell banks intended for large patient populations, and addressing product heterogeneity due to residual pluripotent cells or partially differentiated progenitors.

7. Invetech Cell & Gene Tech Expo April 2025: Cell Therapy 4/28/2025

   Explore a collaborative approach in diagnostics and cell therapy applications that has successfully addressed manufacturing challenges to enable scalable automation solutions from early-stage development to end-to-end processes.

8. Revolutionizing Cell Therapy Manufacturing With AI 11/7/2024

   Discover how AI can optimize processes, improve efficiency, and enhance the understanding of cellular processes, ultimately leading to more effective and personalized patient treatments.

9. Invetech Bio-Expo Live 2024: Downstream Bioprocessing 8/14/2024

   With the demand for specialized equipment that can effectively meet evolving needs, learn about innovative solutions and gain insights into incorporating scalability from the early stages of equipment development.

10. Inside Next-Gen Platforms For Cell Therapy Manufacturing | Audience Q&A 7/3/2024

    In one of our most active Cell & Gene Live audience Q&As to date, Will Junker and Nick Siciliano responded to several audience questions ranging in scope from reducing environmental control requirements with respect to total COGs for cell therapy manufacturing to the technologies that benefit in closing of processes.